{"id":62297,"date":"2026-04-03T16:55:17","date_gmt":"2026-04-03T08:55:17","guid":{"rendered":"https:\/\/flcube.com\/?p=62297"},"modified":"2026-04-03T16:55:18","modified_gmt":"2026-04-03T08:55:18","slug":"zhifei-biological-renews-exclusive-china-distribution-pact-with-merck-for-gardasil-9-rotateq-and-pneumovax-shifts-to-demand-driven-supply-model","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62297","title":{"rendered":"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model"},"content":{"rendered":"\n<p><strong>Chongqing Zhifei Biological Products Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300122:SHE\">SHE: 300122<\/a>) announced the renewal of its long-standing <strong>supply, distribution, and co-promotion agreement<\/strong> with <strong>Merck &amp; Co., Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>). Under the revised deal, Zhifei retains <strong>exclusive rights<\/strong> to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including <strong>Gardasil 9 (9-valent HPV)<\/strong>, <strong>Rotateq (pentavalent rotavirus)<\/strong>, and <strong>Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine)<\/strong> under the <strong>Merck Sharp &amp; Dohme<\/strong> trademark.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-terms-of-the-revised-agreement\">Key Terms of the Revised Agreement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Change vs. Prior Agreements<\/th><\/tr><\/thead><tbody><tr><td><strong>Purchase Commitment<\/strong><\/td><td><strong>No fixed base volume<\/strong>\u2014replaced with <strong>rolling, demand-based procurement<\/strong><\/td><\/tr><tr><td><strong>Supply Planning<\/strong><\/td><td>Annual purchase plans to be jointly confirmed based on <strong>anticipated market demand<\/strong> and <strong>actual vaccination rates<\/strong><\/td><\/tr><tr><td><strong>Product Portfolio<\/strong><\/td><td>Expanded to include <strong>three core Merck vaccines<\/strong>, reinforcing Zhifei\u2019s position as Merck\u2019s primary China vaccine partner<\/td><\/tr><tr><td><strong>Commercial Flexibility<\/strong><\/td><td>Greater alignment with real-world uptake, reducing inventory risk and improving supply chain responsiveness<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>This marks a strategic evolution from the rigid, multi-billion-dollar fixed-volume contracts of the past\u2014most notably the <strong>RMB 18.02 billion (USD 2.67B)<\/strong> 2018\u20132021 deal and the <strong>USD 14.8 billion<\/strong> 2023 revision\u2014toward a more agile, market-responsive partnership.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-historical-context-amp-partnership-milestones\">Historical Context &amp; Partnership Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2011:<\/strong> Initial partnership formed; Zhifei appointed Merck\u2019s exclusive vaccine distributor in mainland China.<\/li>\n\n\n\n<li><strong>2017:<\/strong> Four-valent <strong>Gardasil<\/strong> approved in China after six-year regulatory review.<\/li>\n\n\n\n<li><strong>2018:<\/strong> <strong>Gardasil 9<\/strong> received conditional approval; same year, parties signed RMB 18.02B supply pact.<\/li>\n\n\n\n<li><strong>2023:<\/strong> Agreement scaled up to <strong>USD 14.8B<\/strong>, reflecting surging HPV vaccine demand.<\/li>\n\n\n\n<li><strong>2026:<\/strong> Transition to <strong>flexible, rolling procurement<\/strong> model signals maturity of China\u2019s vaccine market and confidence in sustained demand.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Zhifei:<\/strong> Solidifies dominance in China\u2019s premium vaccine import segment and ensures continued access to Merck\u2019s high-margin, high-demand products.<\/li>\n\n\n\n<li><strong>For Merck:<\/strong> Maintains strong commercial foothold in China\u2014the world\u2019s second-largest pharmaceutical market\u2014without bearing local distribution complexity.<\/li>\n\n\n\n<li><strong>Market Impact:<\/strong> The shift away from fixed quotas may ease past supply-demand imbalances that led to shortages (e.g., Gardasil waiting lists) or overstock risks.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HPV Vaccination Gap:<\/strong> Only ~10% of eligible Chinese women have completed HPV vaccination; significant upside remains for <strong>Gardasil 9<\/strong>.<\/li>\n\n\n\n<li><strong>Public Health Push:<\/strong> China\u2019s \u201cHealthy China 2030\u201d initiative prioritizes cancer prevention, supporting long-term vaccine adoption.<\/li>\n\n\n\n<li><strong>Revenue Visibility:<\/strong> While near-term revenue is less predictable without fixed volumes, the <strong>demand-linked model<\/strong> better reflects sustainable market growth.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, market demand, and partnership dynamics. Actual results may vary due to regulatory changes, public health policies, and competitive pressures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u667a\u98de\u751f\u7269\uff1a\u5173\u4e8e\u4e0e\u9ed8\u6c99\u4e1c\u8c03\u6574\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u667a\u98de\u751f\u7269\uff1a\u5173\u4e8e\u4e0e\u9ed8\u6c99\u4e1c\u8c03\u6574\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-e40a03a1-6224-4616-b66a-23658dd8c2d3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u667a\u98de\u751f\u7269\uff1a\u5173\u4e8e\u4e0e\u9ed8\u6c99\u4e1c\u8c03\u6574\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\">\u667a\u98de\u751f\u7269\uff1a\u5173\u4e8e\u4e0e\u9ed8\u6c99\u4e1c\u8c03\u6574\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u667a\u98de\u751f\u7269\uff1a\u5173\u4e8e\u4e0e\u9ed8\u6c99\u4e1c\u8c03\u6574\u6218\u7565\u5408\u4f5c\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e40a03a1-6224-4616-b66a-23658dd8c2d3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[120,176,903,879,12,878],"class_list":["post-62297","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-merck","tag-msd","tag-nyse-mrk","tag-she-300122","tag-vaccine","tag-zhifei-biological"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck &amp; Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp &amp; Dohme trademark.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62297\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model\" \/>\n<meta property=\"og:description\" content=\"Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck &amp; Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp &amp; Dohme trademark.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62297\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-03T08:55:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-03T08:55:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62297#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62297\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model\",\"datePublished\":\"2026-04-03T08:55:17+00:00\",\"dateModified\":\"2026-04-03T08:55:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62297\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Merck\",\"MSD\",\"NYSE: MRK\",\"SHE: 300122\",\"Vaccine\",\"Zhifei Biological\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62297#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62297\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62297\",\"name\":\"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-03T08:55:17+00:00\",\"dateModified\":\"2026-04-03T08:55:18+00:00\",\"description\":\"Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck & Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp & Dohme trademark.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62297#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62297\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62297#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model - Insight, China&#039;s Pharmaceutical Industry","description":"Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck & Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp & Dohme trademark.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62297","og_locale":"en_US","og_type":"article","og_title":"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model","og_description":"Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck & Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp & Dohme trademark.","og_url":"https:\/\/flcube.com\/?p=62297","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-03T08:55:17+00:00","article_modified_time":"2026-04-03T08:55:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62297#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62297"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model","datePublished":"2026-04-03T08:55:17+00:00","dateModified":"2026-04-03T08:55:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62297"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Merck","MSD","NYSE: MRK","SHE: 300122","Vaccine","Zhifei Biological"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62297#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62297","url":"https:\/\/flcube.com\/?p=62297","name":"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-03T08:55:17+00:00","dateModified":"2026-04-03T08:55:18+00:00","description":"Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck & Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp & Dohme trademark.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62297#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62297"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62297#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax\u2014Shifts to Demand-Driven Supply Model"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62297"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62297\/revisions"}],"predecessor-version":[{"id":62299,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62297\/revisions\/62299"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}